Literature DB >> 8898421

Fecal marker variability in colorectal cancer: calprotectin versus hemoglobin.

J A Gilbert1, D A Ahlquist, D W Mahoney, A R Zinsmeister, J Rubin, R D Ellefson.   

Abstract

BACKGROUND: Blood products like hemoglobin are problematic as markers for colorectal neoplasia because bleeding is intermittent. Levels of calprotectin, a leukocyte-derived protein, are increased in stools from colorectal cancer patients. However, this blood constituent may gain luminal access via interstitial leukocyte migration, which could be a less variable mechanism of entry than bleeding.
METHODS: To correlate the levels of and to compare the variability of fecal calprotectin and hemoglobin, quantitative assays were performed independently on multiple serially collected stools from 14 patients with colorectal cancer. Marker level association was estimated with Pearson's correlation coefficient, and variation estimated with an analysis of variance model.
RESULTS: Fecal calprotectin and hemoglobin levels were discordant in 55 (50%) of 110 matched aliquots, and marker levels failed to correlate. The estimated between-subject correlation was -0.10 (95% CI, -0.60 to 0.46), and mean within-subject correlation -0.27 (95% CI, -0.73 to 0.34). The between-stool coefficient of variation was less for calprotectin (22%) than for hemoglobin (80%).
CONCLUSIONS: In patients with colorectal cancer, the mechanism of luminal calprotectin entry appears to be both different from and less erratic than bleeding.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8898421     DOI: 10.3109/00365529609003120

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  6 in total

Review 1.  Functional and clinical aspects of the myelomonocyte protein calprotectin.

Authors:  B Johne; M K Fagerhol; T Lyberg; H Prydz; P Brandtzaeg; C F Naess-Andresen; I Dale
Journal:  Mol Pathol       Date:  1997-06

2.  Faecal calprotectin levels in a high risk population for colorectal neoplasia.

Authors:  O Kronborg; M Ugstad; P Fuglerud; B Johne; J Hardcastle; J H Scholefield; K Vellacott; V Moshakis; J R Reynolds
Journal:  Gut       Date:  2000-06       Impact factor: 23.059

3.  Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma.

Authors:  J Tibble; G Sigthorsson; R Foster; R Sherwood; M Fagerhol; I Bjarnason
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

4.  The role of faecal calprotectin in diagnosis and staging of colorectal neoplasia: a systematic review and meta-analysis.

Authors:  Fiona A Ross; James H Park; David Mansouri; Emilie Combet; Paul G Horgan; Donald C McMillan; Campbell S D Roxburgh
Journal:  BMC Gastroenterol       Date:  2022-04-09       Impact factor: 3.067

5.  Diagnostic accuracy of fecal calprotectin in predicting significant gastrointestinal diseases.

Authors:  Yee Man Kan; Sin Yan Chu; Ching Kong Loo
Journal:  JGH Open       Date:  2021-05-06

6.  Pre-diagnostic faecal calprotectin levels in patients with colorectal cancer: a retrospective study.

Authors:  Nathalie Blad; Richard Palmqvist; Pontus Karling
Journal:  BMC Cancer       Date:  2022-03-24       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.